Radiofrequency Ablation (RFA): Minimally invasive RFA in T1a renal carcinomas
Study summary
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I
Inclusion Criteria:
* Age ≥18 years
* Signed informed consent approved by the Ethics Committee prior to the ablation procedure.
* RCC in stage T1a (size \<4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation
* Absence of comorbidities that contraindicate treatment
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening.
Exclusion Criteria:
* No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.
Primary outcome measure(s)
Technical success — up to 2 months post-procedure ablation zone evaluated post-ablation
Technical efficacy — up to 12 months Abscence of tumor recurrence within the margin of the ablation zone or viable residual tumor on follow-up imaging
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
